Gene · 2224
FDPS: farnesyl diphosphate synthase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FDPS: farnesyl diphosphate synthase. Genes, record 2224. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2224
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P14324 | Farnesyl pyrophosphate synthase | 419 | 92 | Ensembl, GeneID, HGNC |
Source UniProt
Patents52
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 45861 | P14324 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 45862 | P14324 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 7328 | P14324 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7276 | P14324 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5255 | P14324 | Espacenet |
| US 12433933 B2 | 2025-10-07 | 1 | P14324 | Espacenet |
| US 12433933 B2 | 2025-10-07 | 21 | P14324 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7276 | P14324 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 7328 | P14324 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5255 | P14324 | Espacenet |
1 to 10 of 52
See all 52 patentsDrugs11
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALENDRONATE SODIUM | CHEMBL675 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| ALENDRONIC ACID | CHEMBL870 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| IBANDRONATE SODIUM | CHEMBL3989569 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| IBANDRONIC ACID | CHEMBL997 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| MINODRONIC ACID | CHEMBL319144 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| PAMIDRONATE DISODIUM | CHEMBL3989401 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| PAMIDRONIC ACID | CHEMBL834 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| RISEDRONATE SODIUM | CHEMBL1654 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| RISEDRONIC ACID | CHEMBL923 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
| ZOLEDRONIC ACID | CHEMBL4303669 | Farnesyl diphosphate synthase inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 11
See all 11 drugsTrials413
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07471880 | ALENDRONIC ACID | PHASE2 | ClinicalTrials.gov | |
| NCT07471815 | RISEDRONATE SODIUM | PHASE2 | ClinicalTrials.gov | |
| NCT07471516 | ZOLEDRONIC ACID | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07406685 | ZOLEDRONIC ACID | PHASE4 | ClinicalTrials.gov | |
| NCT07406685 | IBANDRONIC ACID | PHASE4 | ClinicalTrials.gov | |
| NCT07281586 | ZOLEDRONIC ACID | PHASE4 | ClinicalTrials.gov | |
| NCT07242612 | ALENDRONIC ACID | ClinicalTrials.gov | ||
| NCT07242612 | RISEDRONIC ACID | ClinicalTrials.gov | ||
| NCT07242612 | IBANDRONIC ACID | ClinicalTrials.gov | ||
| NCT07216794 | ALENDRONIC ACID | PHASE2 | ClinicalTrials.gov |
1 to 10 of 413
See all 413 trialsNIH grants1,349
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FDPS papers | Newest fiscal year |
|---|---|---|---|
| P30CA086862 | Cancer Center Support Grant | 12 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 10 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| R01GM056838 | Structure and Function of Biosynthetic Enzymes | 6 | 2025 |
| P01CA100730 | Retrovirus Models of Cancer | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| R01CA258621 | Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma | 4 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
1 to 10 of 1,349Source NIH's project files
See all 1,349 nih grantsPapers2,695
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-omics integration reveals tissue-specific biosynthesis of sesquiterpenoids in the medicinal plant Eupatorium lindleyanum. | PLoS One | 2026 | 42821537 | PubTator, text mining | PubMed |
| Gypenosides Damulin A and Damulin B Inhibit Hepatocellular Carcinoma by Regulating Cholesterol Synthesis. | Drug Dev Res | 2026 | 42750477 | PubTator, text mining | PubMed |
| An Investigation to Study Morphology, Nanomechanical Attributes, Transcriptomics, and Proteomics of Tumor Associated Macrophages Derived Extracellular Vesicles in the Tumor Microenvironment. | J Anal Oncol | 2026 | 42719843 | PubTator, text mining | PubMed |
| Postzygotic biallelic inactivation of FDFT1 underlies solitary lesion formation in porokeratosis of Mibelli. | J Dermatol Sci | 2026 | 42716848 | PubTator, text mining | PubMed |
| Β-Sitosterol-imidazolium ionic liquid conjugates: synthesis, computational evaluation, and anticancer activity against colorectal cancer cells. | Steroids | 2026 | 42486216 | PubTator, text mining | PubMed |
| Integrative analysis of gastric tissue transcriptomes and gastric cancer GWAS implicates candidate susceptibility genes. | Am J Hum Genet | 2026 | 42392035 | PubTator, text mining | PubMed |
| De Novo Transcriptomic Profiling of Piper chaba: Elucidating the Genetic Basis of Piperine Biosynthesis and Metabolic Pathways. | Int J Genomics | 2026 | 42370307 | PubTator, text mining | PubMed |
| The Effects of Bisphosphonates Used in Osteoporosis Treatment on Breast Cancer: Analysis with Integrative Bioinformatics Methods, DFT, ADMET and Molecular Docking Analysis. | Biology (Basel) | 2026 | 42345808 | PubTator, text mining | PubMed |
| A study to assess the levels of free protein S in pregnant and nonpregnant women in a tertiary care center in Western Maharashtra. | Asian J Transfus Sci | 2026 | 42344662 | PubTator, text mining | PubMed |
| Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib. | Front Oncol | 2026 | 42326324 | PubTator, text mining | PubMed |
1 to 10 of 2,695
See all 2,695 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2224
GET https://conductscience.org/api/genes/v1/2224/patents?page=2